Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET
Company Participants
Jennifer Good – President and Chief Executive Officer
Lisa Delfini – Chief Financial Officer
Bill Forbes – Chief Development Officer
Conference Call Participants
Annabel Samimy – Stifel
Serge Belanger – Needham & Company
Leland Gershell – Oppenheimer
Nathan Weinstein – Aegis
Operator
Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
Various remarks that management makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon.
In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views change.
I would now like to turn the conference over to Jennifer Good, Trevi's President and CEO. Please go ahead.
Jennifer Good
Good afternoon. And thank you for joining our second quarter earnings call and business update. Joining me today on this call are Lisa Delfini, Trevi's Chief Financial Officer; and Dr. Bill Forbes, Trevi's Chief Development Officer. Lisa and I have some prepared remarks, then the three of us will be available for questions at the end.
This has been an exciting year for Trevi and the second quarter was no exception. After reporting out positive interim cost data in the first quarter, in the second quarter we read out our prurigo nodularis trial, or PN, which was also statistically significant. We believe this was an important validation of the unique mechanism of Haduvio, which works both centrally and peripherally and is important in the conditions we have targeted.
Cough and idiopathic pulmonary fibrosis, or IPF, and pruritus and PN represent some of the most severe aspects of these diseases. And we believe there is a potential opportunity to affect the underlying disease in both of these conditions. For example, we were able to show the healing of the excoriations on the PN trial with 55% of Haduvio subjects showing at least a one-category improvement in the five-point Prurigo Activity Scale versus 38% on placebo with a p-value of 0.006 at week 14.